Pharmacologic therapy of cor pulmonale

Area of Science:

• Pulmonary Medicine
• Cardiology
• Respiratory Diseases

Background:

• Chronic Obstructive Pulmonary Disease (COPD) frequently leads to pulmonary hypertension and right ventricular failure.
• Oxygen therapy is a primary treatment, improving pulmonary hemodynamics and right ventricular function.
• Existing therapies for right ventricular hypertrophy and failure in COPD have limitations.

Purpose of the Study:

• To review the current therapeutic strategies for right ventricular failure in COPD patients.
• To evaluate the efficacy of oxygen therapy and other pharmacological interventions.
• To highlight the need for improved understanding and treatment of COPD-related right ventricular failure.

Main Methods:

• Review of existing literature on oxygen therapy, digitalis, diuretics, almitrine, and vasodilators.
• Analysis of the physiological effects of oxygen on the pulmonary vascular bed.
• Discussion of clinical outcomes associated with current treatments.

Main Results:

• Oxygen therapy selectively vasodilates the pulmonary vasculature, reducing pulmonary vascular resistance and right ventricular workload.
• Oxygen improves oxygen delivery, neurologic function, exercise performance, and survival in COPD patients.
• Digitalis and diuretics have specific indications and require careful use; investigational therapies like almitrine and vasodilators show promise but are unproven.

Conclusions:

• Oxygen therapy is the cornerstone for managing pulmonary hypertension and right ventricular failure in COPD.
• Current therapeutic options for established right ventricular hypertrophy and failure are limited.
• Further research into the pathophysiology of ventricular failure in COPD is essential for developing more effective treatments.